CClinicalTrials.gg
CompletedNCT06638671Updated Jun 17, 2026

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

A Phase 4 interventional study of Metformin Hydrochloride and Placebo in Exercise Capacity and Metformin, sponsored by University of Virginia. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University of Virginia · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity.

The main question this study looks to answer is:

  • Does metformin alter exercise capacity?

Participants will:

  • Complete 5 exercise tests on a stationary bike.
  • Undergo a body composition test.
  • Take metformin and placebo.
  • Complete food and symptom logs.

The researchers hypothesize that:

  • Metformin will reduce aerobic capacity.
Read the detailed description

Metformin, a potent biguanide, is the most prescribed glucose-lowering medication for patients newly diagnosed with type 2 diabetes mellitus (T2DM). Metformin has purported utility for various conditions such as aging, autoimmune conditions, and cancer, however, the primary use of metformin is for blood glucose reduction via decreased glucose production in the liver (increased glycogenesis, decreased glycogenolysis and gluconeogenesis), reduced glucose absorption in the gut, and enhanced insulin-independent skeletal muscle glucose uptake. The effect of metformin within skeletal muscle is the focus of this study.

The mechanism for improved metformin-mediated skeletal muscle glucose uptake involves the inhibition of complex 1 (NADH:ubiquinone oxidoreductase) in the mitochondrial electron transport chain (ETC). This leads to a reduced cellular energy charge, marked by a reduced ATP concentration and increased ratios of ADP:ATP and AMP:ATP. This energetic imbalance initiates phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK), which in turn induces glucose transporter (GLUT4) translocation to the cell membrane and upregulates insulin-independent glucose uptake by skeletal muscle fibers. This cellular energy imbalance and subsequent AMPK signaling cascade is similar to stress elicited by exercise. However, during exercise, the energy imbalance is created by increased ATP utilization from skeletal muscle contraction rather than incomplete glucose metabolism (less ATP per glucose) and an increased reliance on glycolysis.

Exercise training is considered the gold standard approach to enhanced cardiorespiratory fitness and peripheral insulin sensitivity across the lifespan. Metformin also benefits glycemic control and reduces cardiovascular risk. Although the evidence is not conclusive, metformin has been shown to potentially decrease exercise capacity in healthy subjects and those with metabolic syndrome. Importantly, due to the increased reliance on anaerobic metabolism, metformin may reduce the lactate threshold (LT) and lactate turn point (LTP), which are strong predictors of perception of effort, submaximal fitness, and endurance performance. Given cardiorespiratory fitness, strength, glucose control, and insulin sensitivity are predictors of disease, disability, and all-cause mortality, it is important to determine the effects of metformin on cardiorespiratory fitness and physical function.

While these mechanisms of metformin in skeletal muscle are compelling for glucose regulation, there is significant variation in the literature on the effects of metformin on exercise capacity, largely due to differences in dosing (e.g., \~50-500 mg/kg) and exercise intervention design (e.g., acute vs. short-term or chronic exercise and/or submaximal vs. maximal exercise intensity). A recent meta-analysis by found that because previous studies have predominantly used exercise intensities well below VO2max, metformin does not appear to affect maximal oxygen uptake in healthy volunteers; metformin may only alter exercise capacity at high or near-maximal work rates. Thus, there is a lack of data on the effects of metformin on lactate threshold, blood lactate clearance, and exercise-induced fatigue.

Data from this study will provide valuable insight into the effects of metformin compared to placebo on exercise capacity at near-maximal work rates in young, healthy adults. While some studies have examined metformin's impact on exercise performance, these tend to be studies where exercise intensity was well below maximal effort, in highly trained cyclists, or in clinical populations (e.g., individuals with T2DM). Importantly, the results from this study may lead healthy individuals to adjust exercise protocols to accommodate for the decline in performance along with an increased perceived exertion that may accompany metformin consumption. Moreover, this study may fill the gap in literature on a slightly longer timeline for metformin ingestion effects on exercise capacity compared to acute consumption, which may have a more profound impact on cardiorespiratory fitness and capacity over time.

02

Conditions studied

  • Exercise Capacity
  • Metformin

Keywords

  • Exercise capacity
  • Metformin
  • Lactate threshold
03

In context

Lead sponsor

University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-30 years old
  • Metformin-naïve
  • BMI \< 30 kg/m2
  • Recreationally active (≥ 3 days/week of exercise)
  • Females must be premenopausal and report normal menstrual cycles
  • Willingness and ability to comply with scheduled visits and study procedures.

Exclusion criteria

Exclusion Criteria:

  • History of cardiometabolic disease, such as type 1 or type 2 diabetes
  • Smoking (must have quit at least 6 mos prior)
  • Use of medication that significantly alters glucose regulation (e.g., metformin, insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, biguanides)
  • Severe liver or kidney disease, or medications to treat liver or kidney disease
  • Pregnant, breastfeeding, or plans to become pregnant during study period
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Metformin (MET)

    At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening. During each treatment phase, participants will consume metformin as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days. Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the placebo treatment phase.

    Drug: Metformin Hydrochloride

  • Placebo comparator
    Placebo (PL)

    At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening. During each treatment phase, participants will consume placebo as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days. Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the metformin treatment phase.

    Drug: Placebo

Interventions

  • DrugMetformin Hydrochloride

    Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.

  • DrugPlacebo

    Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.

06

What researchers measure

Primary outcomes

  1. Exercise capacity

    Exercise capacity will be measured by absolute and relative VO2peak

    Time frame: 6 weeks

  2. Lactate threshold

    Lactate threshold (LT) will be determined by power output immediately before the curvilinear increase in lactate concentration

    Time frame: 6 weeks

  3. VO2 at Lactate threshold

    VO2 at LT denoted as VO2 obtained at the same power output as LT

    Time frame: 6 weeks

  4. Lactate turnpoint (LTP)

    LTP will be determined by the power output obtained immediately before the second sharp increase in blood lactate concentration

    Time frame: 6 weeks

  5. Maximal power output

    Maximal power output (watts) during exercise

    Time frame: 6 weeks

Secondary outcomes

  1. Respiratory exchange ratio (RER)

    RER will be determined during exercise as the ratio of expired CO2 and inspired O2, as an estimate of substrate utilization

    Time frame: 6 weeks

  2. Ventilation (VE)

    Minute ventilation collected during exercise

    Time frame: 6 weeks

  3. Maximal fat oxidation (Fatmax)

    Maximal amount of fat oxidized during exercise

    Time frame: 6 weeks

Other outcomes

  1. Resting blood pressure

    Blood pressure obtained before exercise in a resting state

    Time frame: 6 weeks

  2. Blood pressure during exercise

    Blood pressure measured during exercise at end of each stage

    Time frame: 6 weeks

  3. Resting heart rate

    Heart rate obtained before exercise in a resting state

    Time frame: 6 weeks

  4. Heart rate during exercise

    Heart rate measured during exercise at end of each stage

    Time frame: 6 weeks

  5. Rating of perceived exertion (RPE)

    Participant-perceived difficulty of exercise recorded at end of each stage during exercise

    Time frame: 6 weeks

07

Study locations

1 site
  • University of Virginia
    Charlottesville, Virginia 22903, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638671
Lead sponsor
University of Virginia
Responsible party
Jason Allen (Associate Professor, University of Virginia) — Principal investigator
First posted
Oct 15, 2024
Start date
Jan 31, 2025
Primary completion
Mar 12, 2026
Completion
Mar 12, 2026
Last update
Jun 17, 2026

Study contacts

Jason D Allen, PhD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion